Evidence map›Paper›PMID 35405781›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2022

[Functional investigation of chimeric antigen receptor T cells targeting LMP1 antigen].

H Z He, Y Y Xing, Y Zhang, Y X Xu, Z Tian, H Y Xing, K J Tang, Q Rao, J X Wang, M Wang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

H Z HeState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Peking Union Medical University, CAMS & PUMC, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Tianjin 300020, China.
Y Y XingState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Peking Union Medical University, CAMS & PUMC, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Tianjin 300020, China.
Y ZhangState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Peking Union Medical University, CAMS & PUMC, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Tianjin 300020, China.
Y X XuState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Peking Union Medical University, CAMS & PUMC, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Tianjin 300020, China.
Z TianState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Peking Union Medical University, CAMS & PUMC, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Tianjin 300020, China.
H Y XingState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Peking Union Medical University, CAMS & PUMC, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Tianjin 300020, China.
K J TangState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Peking Union Medical University, CAMS & PUMC, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Tianjin 300020, China.
Q RaoState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Peking Union Medical University, CAMS & PUMC, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Tianjin 300020, China.
J X WangState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Peking Union Medical University, CAMS & PUMC, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Tianjin 300020, China.
M WangState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Peking Union Medical University, CAMS & PUMC, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Tianjin 300020, China.
Institute of Hematology & Blood Diseases Hospital · CN

Funding

CAMS Initiative Fund for Medical Sciences 2021-I2M-1-041National Key R&D Program of China 2019YFA0110200National Natural Science Foundation of China 81830005
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

LymphomaReceptors, Chimeric AntigenT-LymphocytesViral Matrix ProteinsCell Line, TumorHerpesvirus 4, HumanHumansLentivirusEBV-associated membrane antigen, Epstein-Barr virusReceptors, Chimeric AntigenViral Matrix ProteinsChimeric antigen receptor T cellEpstein-Barr virusLMP1 antigen

Identifiers

PMID35405781
PMCPMC9072074
OpenAlexW4223591251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.